Oral contraceptive use and increased plasma concentration of C-reactive protein

Life Sciences

Volumn 73, Issue 10, 2003, Pages 1245-1252

  Dreon, Darlene M ^a   Slavin, Joanne L ^b   Phinney, Stephen D ^a  

^a Galileo Laboratories Inc   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

C reactive protein; Cardiovascular; Oral contraceptives

Indexed keywords

C REACTIVE PROTEIN; CONTRACEPTIVE AGENT; ESTROGEN; ETHINYLESTRADIOL; ETHINYLESTRADIOL PLUS LEVONORGESTREL; ETHINYLESTRADIOL PLUS NORETHISTERONE; ETHINYLESTRADIOL PLUS NORGESTIMATE; NORGESTREL;

ACCURACY; ADULT; ANALYSIS OF VARIANCE; ARTICLE; CARDIOVASCULAR RISK; CLINICAL RESEARCH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DIET; DIET RESTRICTION; DISEASE MARKER; DRUG EFFECT; FEMALE; FOLLICULAR PHASE; FOOD INTAKE; HORMONE METABOLISM; HUMAN; LABORATORY TEST; LOW DRUG DOSE; LUTEAL PHASE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; NORMAL HUMAN; ORAL CONTRACEPTION; OUTPATIENT DEPARTMENT; PATIENT SELECTION; PREVALENCE; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; RANDOMIZED CONTROLLED TRIAL; SOYBEAN; UNIVERSITY;

EID: 0038353367     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0024-3205(03)00425-9     Document Type: Article

References (41)

1. Burkman R.T. Oral contraceptives: current status. Clinical Obstetrics and Gynecology. 44(1):2001;62-72.
2. Cermak J., Key N.S., Bach R.R., Balla J., Jacob H.S., Vercellotti G.M. C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor. Blood. 82(2):1993;513-520.
3. Connell E.B., Connell J.T. C-reactive protein in pregnancy and contraception. American Journal of Obstetrics and Gynecology. 110(5):1971;633-639.
4. Cushman M., Legault C., Barrett-Connor E., Stefanick M.L., Kessler C., Judd H.L., Sakkinen P.A., Tracy R.P. Effect of postmenopausal hormones on inflammation-sensitive proteins: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Study. Circulation. 100(7):1999;717-722.
5. Danesh J., Collins R., Appleby P., Peto R. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. Journal of the American Medical Association. 279(18):1998;1477-1482.
6. Fernandez-Real J.M., Gutierrez C., Vendrell J., Casamitjana R., Ricart W. Plasma soluble tumor necrosis factor-alpha receptors circulate in proportion to leptin levels during the menstrual cycle in lean but not in obese women. European Journal of Endocrinology. 143(2):2000;235-241.
7. Gillum L.A., Mamidipudi S.K., Johnston S.C. Ischemic stroke risk with oral contraceptives. A meta-analysis. Journal of the American Medical Association. 284(1):2000;72-78.
8. Hulley S., Grady D., Bush T., Furberg C., Herrington D., Riggs B., Vittinghoff E. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Journal of the American Medical Association. 280(7):1998;605-613.
9. Jilma B., Dirnberger E., Loscher I., Rumplmayr A., Hildebrandt J., Eichler H.G., Kapiotis S., Wagner O.F. Menstrual cycle-associated changes in blood levels of interleukin-6, alpha1 acid glycoprotein, and C-reactive protein. Journal of Laboratory and Clinical Medicine. 130(1):1997;69-75.
10. Koenig W., Sund M., Frohlich M., Fischer H.G., Lowel H., Doring A., Hutchinson W.L., Pepys M.B. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation. 99(2):1999;237-242.
11. Konecna L., Yan M.S., Miller L.E., Scholmerich J., Falk W., Straub R.H. Modulation of IL-6 production during the menstrual cycle in vivo and in vitro. Brain, Behavior, and Immunity. 14(1):2000;49-61.
12. Kuller L.H., Tracy R.P., Shaten J., Meilahn E.N. Relationship of C-reactive protein and coronary heart disease in the MRFIT nested case-control study: Multiple Risk Factor Intervention Trial. American Journal of Epidemiology. 144(6):1996;537-547.
13. Lewis M.A., Heinemann L.A., Spitzer W.O., MacRae K.D., Bruppacher R. The use of oral contraceptives and the occurrence of acute myocardial infarction in young women. Results from the transnational study on oral contraceptives and the health of young women. Contraception. 56(3):1997;129-140.
14. Lewis M.A., Spitzer W.O., Heinemann L.A., MacRae K.D., Bruppacher R., Thorogood M. Third generation oral contraceptives and risk of myocardial infarction: an international case-control study. Transnational Research group on oral contraceptives and the health of young women. British Medical Journal. 312(7023):1996;88-90.
15. Lobo R.A., Skinner J.B., Lippman J.S., Cirillo S.J. Plasma lipids and desogestrel and ethinyl estradiol: a meta-analysis. Fertility and Sterility. 65(6):1996;1100-1109.
16. Mariani G., Conard J., Bernardi F., Bertina R., Garcia V.V., Prydz H., Samama M., Sandset P.M., Puopolo M., Ciarla M.V., Poso R., Di Nucci G.D., Ceci F., Marchetti G. Oral contraceptives highlight the genotype-specific association between serum phospholipids and activated factor VII. Arteriosclerosis, Thrombosis, and Vascular Biology. 19(8):1999;2024-2028.
17. Martini M.C., Dancisak B.B., Haggans C.J., Thomas W., Slavin J.L. Effects of soy intake on sex hormone metabolism in premenopausal women. Nutrition and Cancer. 34(2):1999;133-139.
18. Merki-Feld G.S., Imthurn B., Keller P.J. The effect of the menstrual cycle and of ethinylestradiol on nitric oxide, endothelin-1 and homocysteine plasma levels. Hormone and Metabolic Research. 32(7):2000;288-293.
19. Monster T.B., Janssen W.M., de Jong P.E., de Jong-van den Berg L.T. Oral contraceptive use and hormone replacement therapy are associated with microalbuminuria. Archives of Internal Medicine. 161(16):2001;2000-2005.
20. Petitti D.B., Sidney S., Bernstein A., Wolf S., Quensenberry C., Ziel H.K. Stroke in users of low-dose oral contraceptives. New England Journal of Medicine. 335(1):1996;8-15.
21. Ridker P.M., Buring J.E., Shih J., Matias M., Hennekens C.H. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation. 98(8):1998;731-733.
22. Ridker P.M., Hennekens C.H., Rifai N., Buring J.E., Manson J.E. Hormone replacement therapy and increased plasma concentration of C-reactive protein. Circulation. 100(7):1999;713-716.
23. Ridker P.M., Rifai N., Rose L., Buring J.E., Cook N.R. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. New England Journal of Medicine. 347(20):2002;1557-1565.
24. Roberts W.L., Sedrick R., Moulton L., Spencer A., Rifai N. Evaluation of four automated high-sensitivity C-reactive protein methods: implications for clinical and epidemiological applications. Clinical Chemistry. 46(4):2000;461-468.
25. Rosenberg L., Palmer J.R., Rao R.S., Shapiro S. Low-dose oral contraceptive use and the risk of myocardial infarction. Archives of Internal Medicine. 161(8):2001;1065-1070.
26. Rosing J., Middeldorp S., Curvers J., Christella M., Thomassen L.G., Nicolaes G.A., Meijers J.C., Bouma B.N., Buller H.R., Prins M.H., Tans G. Low-dose oral contraceptives and acquired resistance to activated protein C: a randomised crossover study. Lancet. 354(9195):1999;2036-2040.
27. Rossouw J.E., Anderson G.L., Prentice R.L., LaCroix A.Z., Kooperberg C., Stefanick M.L., Jackson R.D., Beresford S.A., Howard B.V., Johnson K.C., Kotchen J.M., Ockene J. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. Journal of the American Medical Association. 288(3):2002;233-321.
28. Scarabin P.Y., Vissac A.M., Kirzin J.M., Bourgeat P., Amiral J., Agher R., Guize L. Elevated plasma fibrinogen and increased fibrin turnover among healthy women who both smoke and use low-dose oral contraceptives-a preliminary report. Thrombosis Haemostasis. 82(3):1999;1112-1116.
29. Spitzer W.O., Faith J.M., MacRae K.D. Myocardial infarction and third generation oral contraceptives: aggregation of recent studies. Human Reproduction. 17(9):2002;2307-2314.
30. Sidney S., Petitti D.B., Quesenbery C.P., Klatsky A.L., Ziel H.K., Wolf S. Myocardial infarction in users of low dose oral contraceptives. Obstetrics and Gynecology. 88(6):1996;939-944.
31. Tanis B.C., van den Bosch M.A., Kemmeren J.M., Cats V.M., Helmerhorst F.M., Algra A., van der Graaf Y., Rosendaal F.R. Oral contraceptives and the risk of myocardial infarction. New England Journal of Medicine. 345(25):2001;1787-1793.
32. Tans G., Curvers J., Middeldorp S., Thomassen M.C., Meijers J.C., Prins M.H., Bouma B.N., Buller H.R., Rosing J. A randomized cross-over study on the effects of levonorgestrel- and desogestrel-containing oral contraceptives on the anticoagulant pathways. Thrombosis Haemostasis. 84(1):2000;15-21.
33. van Baal W.M., Kenemans P., van der Mooren M.J., Kessel H., Emeis J.J., Stehouwer C.D. Increased C-reactive protein levels during short-term hormone replacement therapy in healthy postmenopausal women. Thrombosis Haemostasis. 81(6):1999;925-928.
34. Vandenbroucke J.P., Koster T., Briet E., Reitsma P.H., Bertina R.M., Rosendaal F.R. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet. 344(8935):1994;1453-1457.
35. Vandenbroucke J.P., Rosing J., Bloemenkamp K.W., Middeldorp S., Helmerhorst F.M., Bouma B.N., Rosendaal F.R. Oral contraceptives and the risk of venous thrombosis. New England Journal of Medicine. 344(20):2001;527-535.
36. Walsh B.W., Paul S., Wild R.A., Dean R.A., Tracy R.P., Cox D.A., Anderson P.W. The effects of hormone replacement therapy and raloxifene on C-reactive protein and homocysteine in healthy postmenopausal women: a randomized, controlled trial. Journal of Clinical Endocrinology and Metabolism. 85(1):2000;214-218.
37. West S.G., Stoney C.M., Hughes J.W., Matacin M., Emmons K.M. Oral contraceptive use is associated with increased cardiovascular reactivity in nonsmokers. Annals of Behavioral Medicine. 23(3):2001;149-157.
38. WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception Ischaemic stroke and combined oral contraceptives: results of an international multicentre, case-control study. Lancet. 348(9026):1996;498-505.
39. WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception Haemorrhagic stroke, overall stroke risk, and combined oral contraceptives: results of an international, multicentre, case-control study. Lancet. 348(9026):1996;505-510.
40. WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception Acute myocardial infarction and combined oral contraceptives: results of an international case-control study. Lancet. 349(9060):1997;1202-1209.
41. Wiegratz I., Jung-Hoffman C., Gross W., Kuhl H. Effect of two oral contraceptives containing ethinyl estradiol and gestodene or norgestimate on different lipid and lipoprotein parameters. Contraception. 58(2):1998;83-91.